p53 expression in tumor-stromal fibroblasts is closely associated with the nodal metastasis and outcome of patients with invasive ductal carcinoma who received neoadjuvant therapy

Human Pathology

Volumn 41, Issue 2, 2010, Pages 262-270

  Hasebe, Takahiro ^a   Tamura, Nobuko ^b   Okada, Nao ^b   Hojo, Takashi ^b   Akashi Tanaka, Sadako ^b   Shimizu, Chikako ^b   Tsuda, Histoshi ^b   Shibata, Tatsuhiro ^c   Sasajima, Yuko ^b   Iwasaki, Motoki ^d   Kinoshita, Takayuki ^b  

^a Center for Cancer Control and Information Services   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d NATIONAL CANCER CENTER   (Japan)

Author keywords

Breast cancer; Fibroblast; p53; Prognosis; Tumor stroma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST BIOPSY; CANCER MORTALITY; CONTROLLED STUDY; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PROGNOSIS; PROTEIN EXPRESSION; STROMA; TISSUE SECTION; TUMOR CELL; TUMOR RECURRENCE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 74149094373     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.07.021     Document Type: Article

References (37)

1. Finak G., Bertos N., Pepin F., et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14 (2008) 518-527
2. Sheehan K.M., Gulmann C., Eichler G.S., et al. Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition. Oncogene 27 (2008) 323-331
3. Singer C.F., Gschwantler-Kaulich D., Fink-Retter A., et al. Differential gene expression profile in breast cancer-derived stromal fibroblasts. Breast Cancer Res Treat 110 (2008) 273-281
4. Loussouarn D., Campion L., Sagan C., et al. Prognostic impact of syndecan-1 expression in invasive ductal carcinomas. Br J Cancer 98 (2008) 1993-1998
5. Studebaker A.W., Storci G., Werbeck J.L., et al. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 68 (2008) 9087-9095
6. Hasebe T., Sasaki S., Imoto S., et al. Proliferative activity of intratumoral fibroblasts is closely correlated with lymph node and distant organ metastases of invasive ductal carcinoma of the breast. Am J Pathol 156 (2000) 1701-1710
7. Hasebe T., Sasaki S., Imoto S., et al. Highly proliferative fibroblasts forming fibrotic focus govern metastasis of invasive ductal carcinoma of the breast. Mod Pathol 14 (2001) 325-337
8. Moinfar F., Man Y.G., Arnould L., et al. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implication for tumorigenesis. Cancer Res 60 (2000) 2562-2566
9. Patocs A., Zhang L., Xu Y., et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 357 (2007) 2543-2551
10. Bloom H.J.G., and Richardson W.W. Histological grading and prognosis in breast cancer. Br J Cancer 11 (1957) 359-377
11. Gilchrist K.W., Gray R., Fowble B., et al. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 eastern cooperative oncology group patients. J Clin Oncol 11 (1993) 1929-1935
12. Hasebe T., Tsuda H., Hirohashi S., et al. Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res Treat 49 (1998) 195-208
13. Hasebe T., Sasaki S., Imoto S., et al. Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study. Mod Pathol 15 (2002) 502-516
14. Fisher B. Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primary breast cancer. Cancer 40 (1977) 574-587
15. Fisher B. Adjuvant chemotherapy in the primary management of breast cancer. Med Clin North Am 61 (1977) 953-965
16. Allred D.C., Clark G.M., Elledge R., et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85 (1993) 200-206
17. Allred D.C., Harvey J.M., Berardo M.D., et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11 (1998) 155-168
18. Mohsin S., Weiss H., Havighurst T., et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 17 (2004) 1545-1554
19. Badve S.S., Baehner F.L., Gray R.P., et al. Estrogen- and progesterone-receptor status in ECOG2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 26 (2008) 2473-2481
20. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131 (2007) 18-43
21. Faneyte I.F., Schrama J.G., Peterse J.L., et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 88 (2003) 406-412
22. Taucher S., Rudas M., Mader R.M., et al. Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer. Breast Cancer Res Treat 82 (2003) 207-213
23. Arens N., Bleyl U., and Hildenbrand R. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Arch 446 (2005) 489-496
24. Wang J., Buchholz T.A., Middleton L.P., et al. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. Cancer 94 (2002) 3107-3114
25. von Minckwitz G., Sinn H.P., Raab G., et al. Clinical response after two cycle compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathologic complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 10 (2008) R30
26. Sullivan P.S., and Apple S.K. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?. Breast J 15 (2009) 146-154
27. Fraser M., Bai T., and Tsang B.K. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer 122 (2008) 534-546
28. Dudley A.C., Shin S.C., Cliffe A.R., et al. Attenuated p53 activation in tumor-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine. Br J Cancer 99 (2008) 118-125
29. Lafkas D., Timis G., Papavassiliou A.G., et al. p53 mutations in stromal fibroblasts sensitize tumors against chemotherapy. Int J Cancer 123 (2008) 967-971
30. Bierie B., and Moses H.L. Under pressure: stromal fibroblasts change their ways. Cell 123 (2005) 985-987
31. Hill R., Song Y., Cardiff R.D., et al. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 123 (2006) 1001-1011
32. Kiaris H., Chatzistamou I., Trimis G., et al. Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Res 65 (2005) 1627-1630
33. Allinen M., Beroukhim R., Cai L., et al. Molecular characterization of the tumor microenviroment in breast cancer. Cancer Cell 6 (2004) 17-32
34. Lebret S.C., Newgreen D.F., Thompson E.W., et al. Induction of epithelial to mesenchymal transition in PMC42-LA human breast carcinoma cells by carcinoma-associated fibroblast secreted factors. Breast Cancer Res 9 (2007) R19
35. Campbell I.G., Qiu W., Polyak K., et al. Breast-cancer stromal cells with TP53 mutations. N Engl J Med 10 (2008) 1634-1635
36. Baak J.P., Colpaert C.G., van Diest P.J., et al. Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in node-negative invasive breast cancers. Eur J Cancer 41 (2005) 2093-2101
37. Colpaert C., Vermeulen P.B., van Beest P., et al. Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients. Histopathology 39 (2001) 416-425